IL2 and melanoma: Several cytokines, including monocyte chemoattractant protein 1 (MCP-1), TNF-α [46], IL-6 [47] and IL-2 [48] have been reported to be predictive biomarkers for the response of melanoma patients to ICI treatment or for melanoma metastases [49].